Share on StockTwits

RXi Pharmaceuticals Corp (NASDAQ:RXII) CEO Geert Cauwenbergh bought 2,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 4th. The stock was purchased at an average cost of $2.94 per share, with a total value of $5,880.00. Following the completion of the acquisition, the chief executive officer now directly owns 23,100 shares of the company’s stock, valued at approximately $67,914. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

RXi Pharmaceuticals Corp (NASDAQ:RXII) opened at 2.95 on Friday. RXi Pharmaceuticals Corp has a 52 week low of $2.55 and a 52 week high of $6.84. The stock’s 50-day moving average is $3.15 and its 200-day moving average is $3.94. The company’s market cap is $41.4 million.

RXi Pharmaceuticals Corp (NASDAQ:RXII) last announced its earnings results on Wednesday, May 14th. The company reported ($0.32) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.31) by $0.01. On average, analysts predict that RXi Pharmaceuticals Corp will post $-0.89 earnings per share for the current fiscal year.

RXII has been the subject of a number of recent research reports. Analysts at Laidlaw initiated coverage on shares of RXi Pharmaceuticals Corp in a research note on Monday, June 2nd. They set a “buy” rating and a $8.00 price target on the stock. Separately, analysts at Wainwright initiated coverage on shares of RXi Pharmaceuticals Corp in a research note on Monday, May 5th. They set a “buy” rating and a $9.00 price target on the stock. Finally, analysts at HC Wainwright initiated coverage on shares of RXi Pharmaceuticals Corp in a research note on Monday, May 5th. They set a “buy” rating and a $9.00 price target on the stock.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) is a development-stage company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.